Detalhe da pesquisa
1.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 24(3): 286-296, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37052965
2.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol
; 172: 72-77, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36965291
3.
Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.
Int J Mol Sci
; 24(23)2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38069422
4.
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Br J Cancer
; 127(8): 1479-1486, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35869143
5.
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Int J Gynecol Cancer
; 32(6): 799-803, 2022 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35318277
6.
Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy.
Int J Gynecol Cancer
; 31(1): 110-113, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32796087
7.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Int J Gynecol Cancer
; 31(10): 1348-1355, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34462317
8.
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Lancet Oncol
; 17(8): 1137-1146, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27402147
9.
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.
Proc Natl Acad Sci U S A
; 110(24): 9845-50, 2013 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23697367
10.
High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer.
J Cell Physiol
; 229(1): 53-9, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23765903
11.
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
Eur J Cancer
; 206: 114127, 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38797038
12.
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab.
Clin Pharmacol Ther
; 114(3): 652-663, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243926
13.
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial.
J Exp Clin Cancer Res
; 42(1): 83, 2023 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37041632
14.
The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
J Exp Clin Cancer Res
; 41(1): 245, 2022 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35964058
15.
Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer.
Front Immunol
; 13: 953115, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36119020
16.
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.
Diagnostics (Basel)
; 12(9)2022 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36140519
17.
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.
Cancers (Basel)
; 14(7)2022 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35406620
18.
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.
Nat Med
; 8(10): 1136-44, 2002 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-12244303
19.
From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer.
Immunotherapy
; 13(1): 67-77, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33045887
20.
Epidemiology of antimicrobial resistance (AMR) on California dairies: descriptive and cluster analyses of AMR phenotype of fecal commensal bacteria isolated from adult cows.
PeerJ
; 9: e11108, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33976962